Age-Related P-Glycoprotein Expression in the Intestine and Affecting the Pharmacokinetics of Orally Administered Enrofloxacin in Broilers

Mengjie Guo; Shamsuddin Bughio; Yong Sun; Yu Zhang; Lingling Dong; Xiaohua Dai; Liping Wang

doi:10.1371/journal.pone.0074150

Abstract

Bioavailability is the most important factor for the efficacy of any drug and it is determined by P- glycoprotein (P-gp) expression. Confirmation of P-gp expression during ontogeny is needed for understanding the differences in therapeutic efficacy of any drug in juvenile and adult animals. In this study, Abcb1 mRNA levels in the liver and intestine of broilers during ontogeny were analysed by RT qPCR. Cellular distribution of P-gp was detected by immunohistochemstry. Age-related differences of enrofloxacin pharmacokinetics were also studied. It was found that broilers aged 4 week-old expressed significantly (P<0.01) higher levels of P-gp mRNA in the liver, jejunum and ileum, than at other ages. However, there was no significant (P>0.05) age-related difference in the duodenum. Furthermore, the highest and lowest levels of Abcb1 mRNA expression were observed in the jejunum, and duodenum, respectively. P-gp immunoreactivity was detected on the apical surface of the enterocytes and in the bile canalicular membranes of the hepatocytes. Pharmacokinetic analysis revealed that the 8 week-old broilers, when orally administrated enrofloxacin, exhibited significantly higher C_max (1.97 vs. 0.98 μg•ml^-1, P=0.009), AUC(14.54 vs. 9.35 μg•ml^-1•h, P=0.005) and Ka (1.38 vs. 0.43 h^-1, P=0.032), as well as lower T_peak (1.78 vs. 3.28 h, P=0.048) and T_1/2ka (0.6 vs. 1.64 h, P=0.012) than the 4 week-old broilers. The bioavailability of enrofloxacin in 8 week-old broilers was increased by 15.9%, compared with that in 4 week-old birds. Interestingly, combining verapamil, a P-gp modulator, significantly improved pharmacokinetic behaviour of enrofloxacin in all birds. The results indicate juvenile broilers had a higher expression of P-gp in the intestine, affecting the pharmacokinetics and reducing the bioavailability of oral enrofloxacin in broilers. On the basis of our results, it is recommended that alternative dose regimes are necessary for different ages of broilers for effective therapy.

Citation: Guo M, Bughio S, Sun Y, Zhang Y, Dong L, Dai X, et al. (2013) Age-Related P-Glycoprotein Expression in the Intestine and Affecting the Pharmacokinetics of Orally Administered Enrofloxacin in Broilers. PLoS ONE 8(9): e74150. https://doi.org/10.1371/journal.pone.0074150

Editor: Valerie A. Ferro, University of Strathclyde, United Kingdom

Received: April 1, 2013; Accepted: July 27, 2013; Published: September 16, 2013

Copyright: © 2013 Guo et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported in part by the National Natural Science Foundation of China (No. 30972220), Natural Science Foundation of Jiangsu Province of China (No. BK2012771), the Fundamental Research Funds for the Central Universities (KYZ201105), and the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

ABC transporters can carry a wide range of substrates across biological membranes, by hydrolysing ATP as an energy source [1]. Although these transporters are prone to over-expression in tumours, their expression is widespread throughout many normal tissues such as the liver, kidney and intestine in mammals [2,3,4,5]. P-glycoprotein (P-gp, 170 kDa), a multi-drug resistance gene (also known as Abcb1 gene) product, is the most important transporter for clinically relevant drugs and is the focus of this study. The data from knockout mice suggest that intestinal P-gp may play a direct clinical role in the disposition of orally administered drugs and in explaining certain clinical drug-drug interactions [6,7,8]. The expression of efflux transporters is regulated in a highly dynamic manner [9]. Regarding the physiological changes in P-gp expression, it has been recently suggested that age might affect basal P-glycoprotein levels in human and mice [10,11,12]. Age-related differences have been observed in the pharmacokinetics of the P-gp substrates digoxin [13] and fexofenadine [14]. In poultry, only a few studies [15,16] have partially characterised the expression of P-gp in tissues of chickens and turkeys. There is increasing recognition for the role of P-gp in veterinary therapy [17]. However, it is unknown whether age affects P-gp expression in broilers, because P-gp expression affects the pharmacokinetics of many orally administered drugs, including anti-parasitic and chemotherapeutic drugs in ruminant species [18]. In addition, P-gp modulators can profoundly affect the plasma disposition of chemotherapeutic drugs. Fluoroquinolones have been successfully used for the treatment of colibacillosis and mycoplasma infection in poultry [19,20]. Some of them, such as danofloxacin and gatifloxacin, have proven to be the substrates for ABC transporters [21,22,23,24]. Enrofloxacin is also one of the most extensively used therapeutic agents in poultry. However, very little is known about the role of ABC transporters in the pharmacokinetics of orally administered enrofloxacin in chickens, especially in broilers at different ages.

This study investigated P-gp expression in the liver and small intestines in broilers at different ages (from young adults to slaughter stage), the effect of different P-gp expression levels on enrofloxacin pharmacokinetics in broilers aged 4 and 8 weeks, and also using the P-gp modulator verapamil. This study reveals that juvenile broilers have higher expression of P-gp in the intestine, which affected pharmacokinetics by reducing the bioavailability of orally administered enrofloxacin in the broilers.

Materials and Methods

Reagents and drugs

Mouse monoclonal anti-P-gp (C219) and rabbit polyclonal anti-P-gp antibodies, used for immunohistochemistry, were from Covance (Princeton, New Jersey, USA) and Biossn (Wuhan, Hubei, China), respectively. Rabbit anti-rat IgG-horseradish peroxidase (HRP) was purchased from Boster (Wuhan, Hubei, China). Enrofloxacin hydrochloride (ENRO, bulk drug) was a gift from the China Institute of Veterinary Drug Control (Beijing, China). Verapamil was purchased from Sigma (St. Louis, MO, USA). All other compounds used were reagent grade from local vendors.

Animals and sample collection

Total 20 one-day-old Ross broilers were purchased from a commercial hatchery (Wuxi, China) and raised under standard conditions of light and temperature. Feed (without antibiotics and coccidiostats) and water were provided ad libitum. Tissue samples (duodenum, jejunum, ileum and liver) were collected at 2, 4, 6 and 8 weeks of age, respectively. Five randomly chosen birds were sacrificed by decapitation at predetermined time intervals. After being sub-packaged in aliquots and snap-frozen in liquid nitrogen, all samples were stored at -70°C until real-time RT-PCR analysis was performed. The use of the birds followed the protocol approved by Nanjing Agricultural University Animal Care and Use Committee.

RNA isolation and mRNA quantification

Real time RT-PCR was used to detect the mRNA expression level in liver and different parts of intestine in broilers at different ages. Total RNA was isolated from individual tissues of all birds using Trizol Reagent (Takara, Tokyo, Japan) according to the manufacturer’s instructions. Total RNAs were treated with 100 U DNase I (RNase Free, Takara, Tokyo, Japan) for 30 min at 37°C to ensure that all total RNA was free of genomic DNA contamination. The total RNA concentration was then quantified by Nanodrop photometer (ND-1000 Spectrophotometer, Rockland, DE, USA). Ratios of absorption (260/280 nm) of all preparations were between 1.8 and 2.0. Each RNA sample was subjected to electrophoresis on a 1.4% agarose formaldehyde gel to verify its integrity. Single-stranded cDNAs were synthesised and real-time PCR was performed, as previously described [25]. Negative controls involved the omission of RNA from the RT reactions and amplification with specific primer/probe sets to confirm the lack of genomic DNA contamination. Primers specific for P-gp and β-actin were designed as described [26] and commercially synthesised for real-time PCR analysis. Chicken β-actin was chosen as a housekeeping gene for normalisation, based on experiments showing stable expression of β-actin mRNA in the small intestine and liver in the broilers. The PCR products were sequenced to validate the identity of the amplicons. The 2 ^{− ΔΔCt} method [27] was used to analyse the real-time RT-PCR data.

Immunohistochemistry

To localise P-gp protein expression in liver and small intestine in broilers, immunohistochemistry was performed. As the highest expression of P-gp mRNA was detected in broilers at 4 weeks of age by real-time RT-PCR analysis, the liver and small intestinal samples were randomly collected from 5 broilers aged 4 weeks. Immunostaining was performed on 5 µm paraffin tissue sections mounted on APES-coated slides. After deparafﬁnisation in xylene and rehydration through graded ethanol, endogenous peroxidase activity was blocked with 3% (v/v) H₂O₂ for 15 min. Then, antigen retrieval was performed by heating the sections in 0.01 M citrate buffer (pH 6.0), and nonspecific protein binding sites were blocked with 5% bovine serum albumin (BSA) at 37°C for 30 min. Thereafter, the tissue-sections were incubated overnight at 4°C with the primary antibody (monoclonal anti-P-gp, diluted 1:20; or rabbit anti-P-gp, diluted 1:200). After washing with PBS, the secondary antibody was applied and samples were incubated for 45 min at 37°C. A streptavidin-biotin-complex was added and the specimens were incubated for a further 30 min at 37°C. The P-gp immunoreactivity was visualised with DAB staining, according to the supplier’s instructions. Finally, sections were counterstained with haematoxylin, dehydrated and cleared with xylene and coated with neutral balsam. Sections treated as above, but without the primary antibody, served as negative controls. Monoclonal anti-P-gp (C219) was used to detect P-gp in liver, and intestine. Two semi-quantitative measurements for P-glycoprotein staining were performed by two experimental pathologists in a double-blind analysis by a light microscope (BX45-DP72; OLYMPUS, Tokyo, Japan) equipped with Plan Apo objectives connected to a CCD camera (U-TV0.63XC; OLYMPUS, Tokyo, Japan). The area and IOD labelled for P-glycoprotein (labelled surface area) was analysed in the liver, kidney and small intestinal using a computer-assisted image analysis system (Image-Pro Plus 4.1 software).

Experiments with enrofloxacin in broilers

In total, forty 4 week-old and forty 8 week-old healthy broilers were randomly divided into four groups. The first group received a single dose of 10 mg/kg body weight (b. w.) of enrofloxacin orally through crop tube gavage. The second group was first orally administrated with verapamil (15 mg/kg b. w.) and then enrofloxacin (10 mg/kg b. w.). The third group received a single dose of 10 mg/kg b.w. of enrofloxacin intravenously (i.v.) through the left brachialis vein. The fourth group was first orally administrated with verapamil (15 mg/kg b. w.) and then injected with enrofloxacin (10 mg/kg b. w.). Blood samples were collected from the right brachialis vein prior to treatment and at 5, 15, 45 min and 1, 2, 4, 6, 8, 12 h in plastic tubes after the administration of enrofloxacin in each group. The blood samples were immediately centrifuged at 3 000 g for 15 min and stored at -20°C until analysis.

Assay for enrofloxacin in serum by HPLC

The serum concentrations of enrofloxacin were detected on an Agilent 1200 high-performance liquid chromatography (HPLC) system as described previously with minor modifications [28,29]. Briefly, the samples were thawed at room temperature and centrifuged at 2000 g for 5 min, the supernatant (0.5 ml) was applied to acetonitrile and the organic and water phases were separated by centrifugation. The organic phase was evaporated to dryness under a nitrogen stream and the residue was resuspended with mobile phase solution. Twenty microliters of the mixture were injected into the HPLC column. The composition of the mobile phase was 0.1M phosphoric acid (adjust pH to 3.0 with triethylamine)/acetonitrile (84:16). Chromatographic separations were performed on Kromasil C₁₈ HPLC Columns (5 μm, 25 cm×4.6 mm). The flow rate of the mobile phase was set to 0.85 mL/min. UV absorbance was measured at 278 nm. Drugs were quantified by measuring the peak area.

Download:

Figure 1. Expression of P-gp mRNA in broilers at different ages.

(A) Expression levels of P-gp mRNA in liver, jejunum, ileum and duodenum in broilers at indicated ages, as detected by real time RT PCR. (B) Relative comparison of expression levels of P-gp mRNA in jejunum, ileum and duodenum in 4 week-old broilers, as detected by real time RT PCR. β-actin was used as a reference gene for normalization (n=5). ** difference between ages of tissues (P<0.01).

https://doi.org/10.1371/journal.pone.0074150.g001

Download:

Figure 2. Immunohistochemical staining of P-gp in the liver and intestines of 4 week-old broilers.

Rabbit anti-P-gp polyclonal antibodies and mouse monoclonal anti-P-gp antibody (C219) were used to detect P-gp in duodenum (a), jejunum (b), ileum (c) and liver (d) of broilers, respectively. Bar = 40 μm.

https://doi.org/10.1371/journal.pone.0074150.g002

Pharmacokinetic analysis

Pharmacokinetic calculations were performed on each individual set of data using 3p97 practical pharmacokinetic software (Version 97, Chinese Pharmacologic Association, Beijing, China). The best fit was determined according to the Akaike’s Information Criterion. The area under the concentration-time curve (AUC) was calculated according to the linear trapezoidal method.

Data analysis

All data were presented as mean ± standard error (S.E.), and analysed by one-way ANOVA using SPSS 16.0 for Windows followed by a least-significant difference (LSD) test for individual comparisons. Values of mRNA abundance were expressed as the fold-change relative to the average value of one group. Pharmacokinetic parameters of enrofloxacin were analysed using t-test for independent-samples. The significance level was set at P < 0.05.

Results

Age-dependent mRNA expression in liver and small intestines in broilers

With regard to P-gp expression in broilers during ontogeny, first, we detected the mRNA expression of Abcb1 in broilers at ages from Day 1 to Day 7. However, to our surprise, the expression level of P-gp mRNA was very low in the liver or small intestines from those very young birds (data not shown). Therefore, we focused on studies of broilers aged from 2 to 8 weeks. According to the real-time RT-PCR results, the patterns of mRNA expression in the liver and small intestines (except duodenum) were age-dependent. As shown in Figure 1A, the broilers at 4 weeks of age expressed significantly higher P-gp mRNA levels in the liver, jejunum and ileum, than at other ages (P<0.01). However, no significant age-related difference was detected in P-gp mRNA expression in the duodenum (P>0.05), although variation was observed within each age group. After further analysing the intestinal samples of 4 week-old broilers, the highest expression level of Abcb1 mRNA was observed in the jejunum, while the lowest expression level of Abcb1 mRNA was seen in the duodenum (Figure 1B).

Download:

Figure 3. Semi-quantification of P-gp in liver and intestines of 4 week-old broilers.

The intensity of specific P-gp staining was evaluated by measuring the IOD, area of positive staining using the Image-Pro Plus 4.1. software. Data were shown as mean ± S.E. (n=5) *P<0.05, **P<0.01.

https://doi.org/10.1371/journal.pone.0074150.g003

The cellular localisation and quantification of P-gp in liver and small intestines of broilers

The expression of P-gp protein in the liver and intestine of broilers (4 weeks of age) was further investigated by immunohistochemical studies using the P-gp antibody. No background staining was observed in the negative controls (data not shown). As shown in Figure 2, strong staining was detected in the liver, duodenum, jejunum or ileum. In the duodenum and jejunum, P-gp immunoreactivity was observed on the apical surface of the enterocytes. However, in the ileum, intense staining was visualised in the cytoplasm of the enterocytes. In liver, marked P-gp immunostaining was observed in the bile canalicular membranes of the hepatocytes. To validate our immunohistochemistry results, we semi-quantified the stained liver and small intestine using Image-Pro Plus 4.1 software. After further analysing the intestinal samples of 4 week-old broilers, the highest expression level of P-gp was observed in the jejunum (Figure 3), whereas the lowest expression level of P-gp was seen in the duodenum. Quantification of P-gp staining provided additional validity to our studies from the protein level, which is coincident with the trend of mRNA expression level in the tissues of 4 week-old broilers.

Pharmacokinetics of enrofloxacin with a single application in broilers at different ages

To determine whether P-gp expression level affects the pharmacokinectics of enrofloxacin, the broilers at 4 and 8 weeks of age were selected, based on the highest and lowest levels of P-gp mRNA expression in the liver and intestines of the birds. The plasma concentration-time profiles of enrofloxacin after a single oral administration of enrofloxacin (10 mg/kg b.w.) in broilers at different ages are illustrated in Figure 3, and the relevant pharmacokinetic parameters are shown in Table 1. The results showed that there was a significant difference between the two groups (4 and 8 week-old broilers). As shown in Figure 4, enrofloxacin was detectable in plasma at the first sampling point (0.083 h) in all broilers. The 8 week-old broilers, when orally administered enrofloxacin, exhibited a significantly higher C_max (1.97 vs. 0.98 μg•mL^-1, P=0.009), AUC (14.54 vs. 9.35 μg•mL^-1•h, P=0.005) and K_a (1.38 vs. 0.43 h^-1, P=0.032), as well as a lower T_peak (1.78 vs. 3.28 h, P=0.048) and T_1/2ka (0.6 vs. 1.64 h, P=0.012), compared with the 4 week-old broilers. In addition, the bioavailability of enrofloxacin in 8 week-old broilers was increased by 15.9% compared with that in 4 week-old birds. However, when enrofloxacin was i.v. administered, there were no significant differences of the main parameters between the two groups of broilers (Table 1). These results suggest that the higher expression of P-gp will possibly affect the pharmacokinetics of enrofloxacin, leading to decreased bioavailability of enrofloxacin in the 4 week-old broilers.

Download:

Figure 4. Plasma concentration-time profiles of orally administered enrofloxacin (10 mg/kg b.w.) in the broilers of 4 and 8 week old.

Data represent mean ± S.E. (n=10).

https://doi.org/10.1371/journal.pone.0074150.g004

Parameters	4 week old broilers	8 week old broilers
Oral administration
Ka (h^-1)	0.43±0.09	1.38±0.7^*
t_1/2ka (h)	1.64±0.33	0.6±0.27^**
T_peak (h)	3.28±0.35	1.78±0.4^*
C_max (μg•mL^-1)	0.98±0.1	1.97±0.54^**
AUC (μg•mL^-1•h)	9.35±1.12	14.54±2.3^**
t_1/2ke (h)	3.36±0.40	3.79±1.24
Cl/f (mL/min)	1.08±0.12	0.7±0.1
i.v. administration
t_1/2 (h)	4.52±0.47	5.23±1.5
AUC (μg•mL^-1•h)	28.1±1.00	29.55±1.23
Cll/f (mL/min)	0.34±0.05	0.33±0.013
F (%)	33.3	49.2

Table 1. Parameters of enrofloxacin, both orally and i.v. administered (10 mg/kg), in 4 and 8 week-old broilers (mean ± S.E., n=10).

CSV

Download CSV

Download:

Figure 5. Plasma concentration-time profiles of orally administered enrofloxacin (10 mg/kg b.w.) in the presence and absence of verapamil (15 mg/kg b.w.) in the broilers of 4 week old (A) and 8 week old (B).

Data represent mean ± S.E. (n=10).

https://doi.org/10.1371/journal.pone.0074150.g005

Download:

Figure 6. Plasma concentration-time profiles of i.v. treated enrofloxacin (10 mg/kg b.w.) in the presence of verapamil (15 mg/kg b.w.) in the broilers aged 4 weeks (A) and 8 weeks old (B).

Data represent mean ± S.E. (n=10).

https://doi.org/10.1371/journal.pone.0074150.g006

Effect of verapamil on pharmacokinetics of orally administrated enrofloxacin

To substantiate the effect of P-gp expression level on the pharmacokinetics of enrofloxacin in broilers, verapamil, an inhibitor of P-gp expression [30], was employed. The mean plasma concentration-time profiles of oral enrofloxacin (10 mg/kg b. w.) in the presence or absence of oral verapamil (15 mg/kg b.w.) are shown in Figure 5. The relevant pharmacokinetic parameters are also listed in Table 2. The combination of enrofloxacin and verapamil caused significant changes in the pharmacokinetic behaviour of enrofloxacin. Compared to enrofloxacin alone, the combination of enrofloxacin/verapamil significantly increased the AUC _0-∞ of enrofloxacin by 2.16- and 1.69-fold (P<0.01), and the C_max of enrofloxacin by 1.46- and 1.17-fold (P<0.05) in 4 and 8 week-old broilers, respectively. Also, the T_1/2ka and T_peak of enrofloxacin were lower after the co-administration of verapamil (P<0.05) in both 4 and 8 week-old broilers. The results support the notion that the level of P-gp profoundly impacts the pharmacokinetics of orally administered enrofloxacin in broilers.

Parameters	4 week old broilers		8 week old broilers
	ENRO	ENRO+VER	ENRO	ENRO+VER
Oral administration
Ka (h^-1)	0.43±0.09	1.02±0.53	1.38±0.7	2.98±0.57^#
t_1/2ka (h)	1.64±0.33	0.79±0.31^*	0.6±0.27	0.24±0.04^#
T_peak (h)	3.28±0.35	2.86±0.93	1.78±0.4	1.11±0.29^#
C_max (μg•mL^-1)	0.98±0.1	1.43±0.15^*	1.97±0.54	2.3±0.74^#
AUC (μg•mL^-1•h)	9.35±1.12	20.24±4.49^**	14.54±2.3	24.63±4.53^##
t_1/2β (h)	3.36±0.4	8.43±3.30*	3.79±1.24	6.58±4.5^#
Cl/f(mL/min)	1.08±0.12	0.51±0.10**	0.7±0.10	0.54±0.27
i.v. administration
t_1/2 (h)	4.52±0.47	4.61±0.61	5.23±1.5	7.15±2.14
AUC (μg•mL^-1•h)	28.1±1.00	27.14±2.58	29.55±1.23	30.83±3.12
CL/F (mL/min)	0.34±0.05	0.37±0.04	0.33±0.013	0.33±0.03
F（%)	33.3	74.6^*	49.2	79.9^#

Table 2. Parameters of enrofloxacin, both orally and i.v. administered (10 mg/kg), in 4 and 8 week-old broilers in the presence and absence of verapamil (15 mg/kg) (mean ± S.E., n=10).

CSV

Download CSV

Effect of verapamil on pharmacokinetics of i.v. administered enrofloxacin

Because the plasma AUC is determined by both uptake and elimination, we also treated broilers with enrofloxacin given by i.v. injection. After i.v. administration, the maximum plasma levels of enrofloxacin were almost equal in the presence or absence of verapamil in both 4 and 8 week-old broilers (Figure 6). The effect of verapamil on the pharmacokinetic parameters is shown in Table 2. The combination of enrofloxacin/verapamil caused no significant changes in the pharmacokinetic behaviour of enrofloxacin. As shown in Table 2, the presence of verapamil did not significantly alter the t_1/2, AUC and CL (P>0.05) of i.v. administered enrofloxacin, in broilers of the two chosen ages. Relative to their respective plasma AUC values after oral drug administration, the estimated bioavailability after oral administration (AUC_oral/AUC_i.v. ×100%) for 4 week-old broilers was 74.6% and 33.3% in the presence and absence of verapamil, respectively, and 79.9% and 49.2% in the presence and absence of verapamil, respectively, for 8 week-old broilers.

Discussion

P-gp is a key molecule in determining not only the resistance of cancer cells against chemotherapeutic drugs but also the disposition of a variety of drugs in the intestine and other tissues [1]. Knowledge of ontogenic expression of P-gp involved in distribution and elimination of drugs is important to interpret the differences in therapeutic efficacy and safety between juvenile and adult animals. Age-dependent expression of P-gp in mammals has been extensively studied [10,12,31]; however, related information in chickens is not available. This prompted us to study the expression pattern of P-gp in the liver and different parts of the intestine of broilers at different ages (2~8 weeks old), corresponding to the stages in poultry husbandry. Here, for the first time, we show that the expression of P-gp mRNA peaked at 4 weeks, and then declined with age. Of greater importance, our results strongly suggest that the age-related expression of P-gp had a serious impact on the pharmacokinetics and bioavailability of oral enrofloxacin in broilers.

Examination of tissue-specific gene expression of P-gp together with its developmental difference is the first step to assess its physiological function in broilers. Our results of the organ and cellular distribution of P-gp in broilers were in agreement with previously reported findings in rodents and humans [32,33,34]. Limited studies have examined the ontogenic expression of P-gp in rats and chickens, but discrepant observations were reported [16,35,36]. Rosati et al. [36] found that mdr1 a/b level increased in liver and kidney in rats continuously until Day 60, then declined in all tissues with age, particularly during the period of 5-8 months old. In contrast, Kamath and Morris [37] found no difference in liver P-gp activity or protein level between young (22 days) and adult rats. Barnes [16] assessed P-gp expression in broilers from 0 to 21 days of age and found that it increased in the liver and kidney over the first few days of life with an apparent plateau at Day 2 and Day 4, respectively; however, the level in the duodenum did not significantly change with age. We found that P-gp mRNA expression was very low in the liver or small intestines in broilers from Day 1 to Day 7 (data not shown), and increased in a time-dependent manner at the early growing stage, peaking at 4 weeks of age in the liver, jejunum and ileum, before declining (Figure 1A). The ontogenic expression of P-gp in the duodenum reported in this study is in line with that published by Barnes [16], but the results for the liver are in sharp contrast to other reports. It is likely that this is due to different animals or feeds used. Further investigation is needed to address this issue.

The factors responsible for the age-dependent changes in P-gp expression are still unclear. However, Demeule et al. [38] and Iqbal et al. [39] have independently demonstrated that the expression of P-gp is up-regulated by steroids and other hormones whose activity may change during aging. Whether endogenous and/or exogenous (feed) hormones affect ontogenic P-gp expression in chickens needs further investigation. We speculate that the difference of P-gp expression peak between birds and mammals is probably related to the fact that birds consume a complex mixture of plant-based nutrients or non-nutritive material upon hatching, and thus birds might have earlier high levels of P-gp in response to the presence of substrates in the diet than mammals.

In addition, although enrofloxacin is available in an oral dosage form, the bioavailability of the oral form is lower than that of subcutaneous or intravenous forms in chicken, sheep and swine [40,41,42]; this has been ascribed to the metabolising enzymes within the intestines and the liver. Also, P-gp affects the absorption of enrofloxacin [43]. Considering that enrofloxacin is a substrate of P-gp [43], the modulation of P-gp expression level and activity may cause significant changes in the pharmacokinetic profiles of enrofloxacin. The C_max, T_peak, AUC and bioavailability of oral enrofloxacin in the broilers (4 and 8 week-old) in the current study were not in accordance with the values in other studies [40,44,45]. This might be due to different pharmaceutical formulations, or different ages or breeds of birds used in the studies. Li et al. [25] suggested that some excipients could enhance the absorption of a drug from the intestines by inhibiting P-gp. In order to preclude the effect of excipients on P-gp function, bulk drug of enrofloxacin was used in this study. The comparison of the enrofloxacin pharmacokinetics in 4 and 8 week-old broilers with different expression levels of P-gp strongly indicated the potential role of P-gp in enrofloxacin disposition. This is further supported by the finding that verapamil, an inhibitor of P-gp expression, was able to increase the absorption of enrofloxacin. Higher C_max and AUC of enrofloxacin after the co-administration of enrofloxacin/verapamil implied an increase in the absorption of enrofloxacin from the gastrointestinal tract. Although the expression of P-gp mRNA was also observed in the liver, the pharmacokinetics of enrofloxacin after i.v. administration alone or with the presence of verapamil were not significantly altered in both 4 and 8 week-old broilers. Therefore, the elevated bioavailability should result from the increased absorption of enrofloxacin by inhibiting P-gp in the intestine, rather than from decreased biliary excretion through inhibiting P-gp in the liver. Our results were somewhat similar to those reported by Sparreboom et al. [6], who found that the biliary excretion of paclitaxe was the same in P-gp knockout and wild-type mice. Seguin et al. [46] observed a poor oral bioavailability of enrofloxacin in neonatal kittens (2 to 8 weeks old), compared with that in adults; it is possible that the high level of P-gp in the intestine constituted a barrier that limited the absorption of enrofloxacin in kittens. Therefore, we should be aware that not all young animals should receive low doses under all circumstances. For some drugs (e.g. enrofloxacin), higher doses are actually needed to achieve therapeutic concentrations of the drugs in young animals.

In conclusion, age-related changes of P-gp expression in the intestine affect the pharmacokinetics of oral enrofloxacin in broilers. The higher expression of P-gp in the intestine of young broilers results in the low oral bioavailability of enrofloxacin. We expect that the results presented here for enrofloxacin are representative for other substrate drugs transported by P-gp. The findings also suggest that the co-administration of P-gp inhibitors may be an alternative strategy to improve the oral bioavailability and therapeutic efficacy of some other P-gp substrate drugs (e.g. ceftiofur licensed for use in animals) in young broilers. Further studies will focus on P-gp-associated different therapeutic efficiency of enrofloxacin in young and adult broilers challenged with E. coli.

Acknowledgments

The authors would like to thank Prof. Zhang Shuxia, who is a specialist in pathology in Nanjing Agricultural University, for the kind instruction in immunohistochemical techniques. We also thank all other laboratory members for their kind assistance during the collection of blood samples.

Author Contributions

Performed the experiments: MG SB YS YZ LD XD. Analyzed the data: MG LD. Participated in research design: LW. Wrote or contributed to the writing of the manuscript: LW MG SB.

References

1. Chan LM, Lowes S, Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21: 25-51. doi:https://doi.org/10.1016/j.ejps.2003.07.003. PubMed: 14706810.
- View Article
- Google Scholar
2. Kullak-Ublick GA, Beuers U, Paumgartner G (2000) Hepatobiliary transport. J Hepatol 32: 3-18. doi:https://doi.org/10.1053/jhep.2000.8978. PubMed: 10728790.
- View Article
- Google Scholar
3. van Montfoort JE, Hagenbuch B, Groothuis GM, Koepsell H, Meier PJ et al. (2003) Drug uptake systems in liver and kidney. Curr Drug Metab 4: 185-211. doi:https://doi.org/10.2174/1389200033489460. PubMed: 12769665.
- View Article
- Google Scholar
4. Takano M, Yumoto R, Murakami T (2006) Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 109: 137-161. doi:https://doi.org/10.1016/j.pharmthera.2005.06.005. PubMed: 16209890.
- View Article
- Google Scholar
5. Giacomini K, Sugiyama Y (2005) Membrane transporters and drug response. In: LL BruntonBA ChabnerB. Knollman.Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th Edition. McGraw-Hill Companies, New York, New York, USA.
6. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW et al. (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94: 2031-2035. doi:https://doi.org/10.1073/pnas.94.5.2031. PubMed: 9050899.
- View Article
- Google Scholar
7. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ et al. (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101: 289-294. doi:https://doi.org/10.1172/JCI1269. PubMed: 9435299.
- View Article
- Google Scholar
8. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM (1999) Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation 99: 552-557. doi:https://doi.org/10.1161/01.CIR.99.4.552. PubMed: 9927403.
- View Article
- Google Scholar
9. Miller DS, Bauer B, Hartz AM (2008) Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 60: 196-209. doi:https://doi.org/10.1124/pr.107.07109. PubMed: 18560012.
- View Article
- Google Scholar
10. Batetta B, Dessi S, Putzolu M, Sanna F, Spano O et al. (1999) MDR1 gene expression in normal and atherosclerotic human arteries(1). J Vasc Res 36: 261-271.
- View Article
- Google Scholar
11. Warrington JS, Greenblatt DJ, von Moltke LL (2004) The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther 309: 730-736. doi:https://doi.org/10.1124/jpet.103.061234. PubMed: 14757850.
- View Article
- Google Scholar
12. Mangoni AA (2007) The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions. Expert Opin Drug Metab Toxicol 3: 315-320. doi:https://doi.org/10.1517/17425255.3.3.315. PubMed: 17539740.
- View Article
- Google Scholar
13. Hanratty CG, McGlinchey P, Johnston GD, Passmore AP (2000) Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging 17: 353-362. doi:https://doi.org/10.2165/00002512-200017050-00003. PubMed: 11190416.
- View Article
- Google Scholar
14. Simons FE, Simons KJ (1999) Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 36: 329-352. doi:https://doi.org/10.2165/00003088-199936050-00003. PubMed: 10384858.
- View Article
- Google Scholar
15. Edelmann HM, Duchek P, Rosenthal FE, Föger N, Glackin C et al. (1999) Cmdr1, a chicken P-glycoprotein, confers multidrug resistance and interacts with estradiol. Biol Chem 380: 231-241. PubMed: 10195430.
- View Article
- Google Scholar
16. Barnes DM (2001) Expression of P-glycoprotein in the chicken. Comp Biochem Physiol A Mol Integr Physiol 130: 301-310. doi:https://doi.org/10.1016/S1095-6433(01)00389-0. PubMed: 11544075.
- View Article
- Google Scholar
17. Schrickx JA, Fink-Gremmels J (2008) Implications of ABC transporters on the disposition of typical veterinary medicinal products. Eur J Pharmacol 585: 510-519. doi:https://doi.org/10.1016/j.ejphar.2008.03.014. PubMed: 18417119.
- View Article
- Google Scholar
18. Szakács G, Váradi A, Ozvegy-Laczka C, Sarkadi B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13: 379-393. doi:https://doi.org/10.1016/j.drudis.2007.12.010. PubMed: 18468555.
- View Article
- Google Scholar
19. Charleston B, Gate JJ, Aitken IA, Stephan B, Froyman R (1998) Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against Escherichia coli infection in chickens. Antimicrob Agents Chemother 42: 83-87. doi:https://doi.org/10.1093/jac/42.1.83. PubMed: 9449265.
- View Article
- Google Scholar
20. Chansiripornchai N, Sasipreeyajan J (2002) Efficacy of sarafloxacin in broilers after experimental infection with Escherichia coli. Vet Res Commun 26: 255-262. doi:https://doi.org/10.1023/A:1016078222398. PubMed: 12184496.
- View Article
- Google Scholar
21. Kwatra D, Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK (2010) Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. Int J Pharm 395: 114-121. doi:https://doi.org/10.1016/j.ijpharm.2010.05.027. PubMed: 20573570.
- View Article
- Google Scholar
22. Schrickx JA, Fink-Gremmels J (2007) Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters. Br J Pharmacol 150: 463-469. PubMed: 17211460.
- View Article
- Google Scholar
23. Gollapudi S, Thadepalli F, Kim CH, Gupta S (1995) Difloxacin reverses multidrug resistance in HL-60/AR cells that overexpress the multidrug resistance-related protein (MRP) gene. Oncol Res 7: 213-225. PubMed: 8534927.
- View Article
- Google Scholar
24. Prime-Chapman HM, Fearn RA, Cooper AE, Moore V, Hirst BH (2004) Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J Pharmacol Exp Ther 311: 476-484. doi:https://doi.org/10.1124/jpet.104.068775. PubMed: 15210835.
- View Article
- Google Scholar
25. Li R, Hu Y, Ni Y, Xia D, Grossmann R et al. (2011) Leptin stimulates hepatic activation of thyroid hormones and promotes early posthatch growth in the chicken. Comp Biochem Physiol A Mol Integr Physiol 160: 200-206. doi:https://doi.org/10.1016/j.cbpa.2011.06.001. PubMed: 21679771.
- View Article
- Google Scholar
26. Haritova AM, Schrickx JA, Fink-Gremmels J (2007) Functional studies on the activity of efflux transporters in an ex vivo model with chicken splenocytes and evaluation of selected fluoroquinolones in this model. Biochem Pharmacol 73: 752-759. doi:https://doi.org/10.1016/j.bcp.2006.11.015. PubMed: 17188652.
- View Article
- Google Scholar
27. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25: 402-408. doi:https://doi.org/10.1006/meth.2001.1262. PubMed: 11846609.
- View Article
- Google Scholar
28. Idowu OR, Peggins JO (2004) Simple, rapid determination of enrofloxacin and ciprofloxacin in bovine milk and plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal 35: 143-153. doi:https://doi.org/10.1016/j.jpba.2004.01.006. PubMed: 15030889.
- View Article
- Google Scholar
29. Pulido MM, Molina AJ, Merino G, Mendoza G, Prieto JG et al. (2006) Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther 29: 279-287. doi:https://doi.org/10.1111/j.1365-2885.2006.00744.x. PubMed: 16846465.
- View Article
- Google Scholar
30. Muller C, Bailly JD, Goubin F, Laredo J, Jaffrézou JP et al. (1994) Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines. Int J Cancer 56: 749-754. doi:https://doi.org/10.1002/ijc.2910560523. PubMed: 7906257.
- View Article
- Google Scholar
31. Warrington JS, Greenblatt DJ, von Moltke LL (2004) The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther 309: 730-736. doi:https://doi.org/10.1124/jpet.103.061234. PubMed: 14757850.
- View Article
- Google Scholar
32. Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR et al. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287. doi:https://doi.org/10.1177/38.9.1974900. PubMed: 1974900.
- View Article
- Google Scholar
33. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM et al. (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 84: 265-269. doi:https://doi.org/10.1073/pnas.84.1.265. PubMed: 2432605.
- View Article
- Google Scholar
34. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I et al. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84: 7735-7738. doi:https://doi.org/10.1073/pnas.84.21.7735. PubMed: 2444983.
- View Article
- Google Scholar
35. Kamath AV, Morris ME (1998) Functional expression of P-glycoprotein in the hepatic canalicular membrane of developing rats. J Pharmacol Sci 87: 785-786. PubMed: 96096829523982.
- View Article
- Google Scholar
36. Rosati A, Maniori S, Decorti G, Candussio L, Giraldi T et al. (2003) Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. Dev Growth Differ 45: 377-387. doi:https://doi.org/10.1046/j.1440-169X.2003.00699.x. PubMed: 12950279.
- View Article
- Google Scholar
37. Kamath AV, Morris ME (1998) Functional expression of P-glycoprotein in the hepatic canalicular membrane of developing rats. J Pharmacol Sci 87: 300-305. doi:https://doi.org/10.1021/js970290q. PubMed: 96096829523982.
- View Article
- Google Scholar
38. Demeule M, Jodoin J, Beaulieu E, Brossard M, Béliveau R (1999) Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett 442: 208-214. doi:https://doi.org/10.1016/S0014-5793(98)01663-9. PubMed: 9929003.
- View Article
- Google Scholar
39. Iqbal M, Gibb W, Matthews SG (2011) Corticosteroid regulation of P-glycoprotein in the developing blood-brain barrier. Endocrinology 152: 1067-1079. doi:https://doi.org/10.1210/en.2010-1227. PubMed: 21239442.
- View Article
- Google Scholar
40. Knoll U, Glünder G, Kietzmann M (1999) Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. J Vet Pharmacol Ther 22: 239-246. doi:https://doi.org/10.1046/j.1365-2885.1999.00217.x. PubMed: 10499235.
- View Article
- Google Scholar
41. Pozzin JF, Harron DWJ, Nation G, Tinson AH, Sheen R et al. (1997) Pharmacoknetics of enrofloxacin following intravenous/intramuscular/oral administration in Nedji sheep. J Vet Pharmacol Ther 20 (Suppl. 1): 60-61.
- View Article
- Google Scholar
42. Gyrd-Hansen N, Nielsen P (1994) he influence of feed on the oral bioavailability of enrofloxacin, oxytetracycline, penicillin V and spiramycin in pigs [poster communications]. pp. 242-243.
43. Alvarez AI, Pérez M, Prieto JG, Molina AJ, Real R et al. (2008) Fluoroquinolone efflux mediated by ABC transporters. J Pharmacol Sci 97: 3483-3493. doi:https://doi.org/10.1002/jps.21233. PubMed: 18200507.
- View Article
- Google Scholar
44. Conzelman GM, Babish JG, Davidson JN, McMillan RA, Copeland DD (1987) Pharmacokinetics of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-q uinoline- carboxylic acid (BAY Vp 2674) in chickens. Proc West Pharmacol Soc 30: 393-395. PubMed: 3628311.
- View Article
- Google Scholar
45. Anadón A, Martínez-Larrañaga MR, Díaz MJ, Bringas P, Martínez MA et al. (1995) Pharmacokinetics and residues of enrofloxacin in chickens. Am J Vet Res 56: 501-506. PubMed: 7785830.
- View Article
- Google Scholar
46. Seguin MA, Papich MG, Sigle KJ, Gibson NM, Levy JK (2004) Pharmacokinetics of enrofloxacin in neonatal kittens. Am J Vet Res 65: 350-356. doi:https://doi.org/10.2460/ajvr.2004.65.350. PubMed: 15027685.
- View Article
- Google Scholar

[ref1] 1. Chan LM, Lowes S, Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21: 25-51. doi:https://doi.org/10.1016/j.ejps.2003.07.003. PubMed: 14706810.
View Article
Google Scholar

[2] View Article

[3] Google Scholar

[ref2] 2. Kullak-Ublick GA, Beuers U, Paumgartner G (2000) Hepatobiliary transport. J Hepatol 32: 3-18. doi:https://doi.org/10.1053/jhep.2000.8978. PubMed: 10728790.
View Article
Google Scholar

[5] View Article

[6] Google Scholar

[ref3] 3. van Montfoort JE, Hagenbuch B, Groothuis GM, Koepsell H, Meier PJ et al. (2003) Drug uptake systems in liver and kidney. Curr Drug Metab 4: 185-211. doi:https://doi.org/10.2174/1389200033489460. PubMed: 12769665.
View Article
Google Scholar

[8] View Article

[9] Google Scholar

[ref4] 4. Takano M, Yumoto R, Murakami T (2006) Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 109: 137-161. doi:https://doi.org/10.1016/j.pharmthera.2005.06.005. PubMed: 16209890.
View Article
Google Scholar

[11] View Article

[12] Google Scholar

[ref5] 5. Giacomini K, Sugiyama Y (2005) Membrane transporters and drug response. In: LL BruntonBA ChabnerB. Knollman.Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11th Edition. McGraw-Hill Companies, New York, New York, USA.

[ref6] 6. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW et al. (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A 94: 2031-2035. doi:https://doi.org/10.1073/pnas.94.5.2031. PubMed: 9050899.
View Article
Google Scholar

[15] View Article

[16] Google Scholar

[ref7] 7. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ et al. (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101: 289-294. doi:https://doi.org/10.1172/JCI1269. PubMed: 9435299.
View Article
Google Scholar

[18] View Article

[19] Google Scholar

[ref8] 8. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM (1999) Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. Circulation 99: 552-557. doi:https://doi.org/10.1161/01.CIR.99.4.552. PubMed: 9927403.
View Article
Google Scholar

[21] View Article

[22] Google Scholar

[ref9] 9. Miller DS, Bauer B, Hartz AM (2008) Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 60: 196-209. doi:https://doi.org/10.1124/pr.107.07109. PubMed: 18560012.
View Article
Google Scholar

[24] View Article

[25] Google Scholar

[ref10] 10. Batetta B, Dessi S, Putzolu M, Sanna F, Spano O et al. (1999) MDR1 gene expression in normal and atherosclerotic human arteries(1). J Vasc Res 36: 261-271.
View Article
Google Scholar

[27] View Article

[28] Google Scholar

[ref11] 11. Warrington JS, Greenblatt DJ, von Moltke LL (2004) The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther 309: 730-736. doi:https://doi.org/10.1124/jpet.103.061234. PubMed: 14757850.
View Article
Google Scholar

[30] View Article

[31] Google Scholar

[ref12] 12. Mangoni AA (2007) The impact of advancing age on P-glycoprotein expression and activity: current knowledge and future directions. Expert Opin Drug Metab Toxicol 3: 315-320. doi:https://doi.org/10.1517/17425255.3.3.315. PubMed: 17539740.
View Article
Google Scholar

[33] View Article

[34] Google Scholar

[ref13] 13. Hanratty CG, McGlinchey P, Johnston GD, Passmore AP (2000) Differential pharmacokinetics of digoxin in elderly patients. Drugs Aging 17: 353-362. doi:https://doi.org/10.2165/00002512-200017050-00003. PubMed: 11190416.
View Article
Google Scholar

[36] View Article

[37] Google Scholar

[ref14] 14. Simons FE, Simons KJ (1999) Clinical pharmacology of new histamine H1 receptor antagonists. Clin Pharmacokinet 36: 329-352. doi:https://doi.org/10.2165/00003088-199936050-00003. PubMed: 10384858.
View Article
Google Scholar

[39] View Article

[40] Google Scholar

[ref15] 15. Edelmann HM, Duchek P, Rosenthal FE, Föger N, Glackin C et al. (1999) Cmdr1, a chicken P-glycoprotein, confers multidrug resistance and interacts with estradiol. Biol Chem 380: 231-241. PubMed: 10195430.
View Article
Google Scholar

[42] View Article

[43] Google Scholar

[ref16] 16. Barnes DM (2001) Expression of P-glycoprotein in the chicken. Comp Biochem Physiol A Mol Integr Physiol 130: 301-310. doi:https://doi.org/10.1016/S1095-6433(01)00389-0. PubMed: 11544075.
View Article
Google Scholar

[45] View Article

[46] Google Scholar

[ref17] 17. Schrickx JA, Fink-Gremmels J (2008) Implications of ABC transporters on the disposition of typical veterinary medicinal products. Eur J Pharmacol 585: 510-519. doi:https://doi.org/10.1016/j.ejphar.2008.03.014. PubMed: 18417119.
View Article
Google Scholar

[48] View Article

[49] Google Scholar

[ref18] 18. Szakács G, Váradi A, Ozvegy-Laczka C, Sarkadi B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13: 379-393. doi:https://doi.org/10.1016/j.drudis.2007.12.010. PubMed: 18468555.
View Article
Google Scholar

[51] View Article

[52] Google Scholar

[ref19] 19. Charleston B, Gate JJ, Aitken IA, Stephan B, Froyman R (1998) Comparison of the efficacies of three fluoroquinolone antimicrobial agents, given as continuous or pulsed-water medication, against Escherichia coli infection in chickens. Antimicrob Agents Chemother 42: 83-87. doi:https://doi.org/10.1093/jac/42.1.83. PubMed: 9449265.
View Article
Google Scholar

[54] View Article

[55] Google Scholar

[ref20] 20. Chansiripornchai N, Sasipreeyajan J (2002) Efficacy of sarafloxacin in broilers after experimental infection with Escherichia coli. Vet Res Commun 26: 255-262. doi:https://doi.org/10.1023/A:1016078222398. PubMed: 12184496.
View Article
Google Scholar

[57] View Article

[58] Google Scholar

[ref21] 21. Kwatra D, Vadlapatla RK, Vadlapudi AD, Pal D, Mitra AK (2010) Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. Int J Pharm 395: 114-121. doi:https://doi.org/10.1016/j.ijpharm.2010.05.027. PubMed: 20573570.
View Article
Google Scholar

[60] View Article

[61] Google Scholar

[ref22] 22. Schrickx JA, Fink-Gremmels J (2007) Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters. Br J Pharmacol 150: 463-469. PubMed: 17211460.
View Article
Google Scholar

[63] View Article

[64] Google Scholar

[ref23] 23. Gollapudi S, Thadepalli F, Kim CH, Gupta S (1995) Difloxacin reverses multidrug resistance in HL-60/AR cells that overexpress the multidrug resistance-related protein (MRP) gene. Oncol Res 7: 213-225. PubMed: 8534927.
View Article
Google Scholar

[66] View Article

[67] Google Scholar

[ref24] 24. Prime-Chapman HM, Fearn RA, Cooper AE, Moore V, Hirst BH (2004) Differential multidrug resistance-associated protein 1 through 6 isoform expression and function in human intestinal epithelial Caco-2 cells. J Pharmacol Exp Ther 311: 476-484. doi:https://doi.org/10.1124/jpet.104.068775. PubMed: 15210835.
View Article
Google Scholar

[69] View Article

[70] Google Scholar

[ref25] 25. Li R, Hu Y, Ni Y, Xia D, Grossmann R et al. (2011) Leptin stimulates hepatic activation of thyroid hormones and promotes early posthatch growth in the chicken. Comp Biochem Physiol A Mol Integr Physiol 160: 200-206. doi:https://doi.org/10.1016/j.cbpa.2011.06.001. PubMed: 21679771.
View Article
Google Scholar

[72] View Article

[73] Google Scholar

[ref26] 26. Haritova AM, Schrickx JA, Fink-Gremmels J (2007) Functional studies on the activity of efflux transporters in an ex vivo model with chicken splenocytes and evaluation of selected fluoroquinolones in this model. Biochem Pharmacol 73: 752-759. doi:https://doi.org/10.1016/j.bcp.2006.11.015. PubMed: 17188652.
View Article
Google Scholar

[75] View Article

[76] Google Scholar

[ref27] 27. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25: 402-408. doi:https://doi.org/10.1006/meth.2001.1262. PubMed: 11846609.
View Article
Google Scholar

[78] View Article

[79] Google Scholar

[ref28] 28. Idowu OR, Peggins JO (2004) Simple, rapid determination of enrofloxacin and ciprofloxacin in bovine milk and plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Biomed Anal 35: 143-153. doi:https://doi.org/10.1016/j.jpba.2004.01.006. PubMed: 15030889.
View Article
Google Scholar

[81] View Article

[82] Google Scholar

[ref29] 29. Pulido MM, Molina AJ, Merino G, Mendoza G, Prieto JG et al. (2006) Interaction of enrofloxacin with breast cancer resistance protein (BCRP/ABCG2): influence of flavonoids and role in milk secretion in sheep. J Vet Pharmacol Ther 29: 279-287. doi:https://doi.org/10.1111/j.1365-2885.2006.00744.x. PubMed: 16846465.
View Article
Google Scholar

[84] View Article

[85] Google Scholar

[ref30] 30. Muller C, Bailly JD, Goubin F, Laredo J, Jaffrézou JP et al. (1994) Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines. Int J Cancer 56: 749-754. doi:https://doi.org/10.1002/ijc.2910560523. PubMed: 7906257.
View Article
Google Scholar

[87] View Article

[88] Google Scholar

[ref31] 31. Warrington JS, Greenblatt DJ, von Moltke LL (2004) The effect of age on P-glycoprotein expression and function in the Fischer-344 rat. J Pharmacol Exp Ther 309: 730-736. doi:https://doi.org/10.1124/jpet.103.061234. PubMed: 14757850.
View Article
Google Scholar

[90] View Article

[91] Google Scholar

[ref32] 32. Cordon-Cardo C, O’Brien JP, Boccia J, Casals D, Bertino JR et al. (1990) Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287. doi:https://doi.org/10.1177/38.9.1974900. PubMed: 1974900.
View Article
Google Scholar

[93] View Article

[94] Google Scholar

[ref33] 33. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM et al. (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 84: 265-269. doi:https://doi.org/10.1073/pnas.84.1.265. PubMed: 2432605.
View Article
Google Scholar

[96] View Article

[97] Google Scholar

[ref34] 34. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I et al. (1987) Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84: 7735-7738. doi:https://doi.org/10.1073/pnas.84.21.7735. PubMed: 2444983.
View Article
Google Scholar

[99] View Article

[100] Google Scholar

[ref35] 35. Kamath AV, Morris ME (1998) Functional expression of P-glycoprotein in the hepatic canalicular membrane of developing rats. J Pharmacol Sci 87: 785-786. PubMed: 96096829523982.
View Article
Google Scholar

[102] View Article

[103] Google Scholar

[ref36] 36. Rosati A, Maniori S, Decorti G, Candussio L, Giraldi T et al. (2003) Physiological regulation of P-glycoprotein, MRP1, MRP2 and cytochrome P450 3A2 during rat ontogeny. Dev Growth Differ 45: 377-387. doi:https://doi.org/10.1046/j.1440-169X.2003.00699.x. PubMed: 12950279.
View Article
Google Scholar

[105] View Article

[106] Google Scholar

[ref37] 37. Kamath AV, Morris ME (1998) Functional expression of P-glycoprotein in the hepatic canalicular membrane of developing rats. J Pharmacol Sci 87: 300-305. doi:https://doi.org/10.1021/js970290q. PubMed: 96096829523982.
View Article
Google Scholar

[108] View Article

[109] Google Scholar

[ref38] 38. Demeule M, Jodoin J, Beaulieu E, Brossard M, Béliveau R (1999) Dexamethasone modulation of multidrug transporters in normal tissues. FEBS Lett 442: 208-214. doi:https://doi.org/10.1016/S0014-5793(98)01663-9. PubMed: 9929003.
View Article
Google Scholar

[111] View Article

[112] Google Scholar

[ref39] 39. Iqbal M, Gibb W, Matthews SG (2011) Corticosteroid regulation of P-glycoprotein in the developing blood-brain barrier. Endocrinology 152: 1067-1079. doi:https://doi.org/10.1210/en.2010-1227. PubMed: 21239442.
View Article
Google Scholar

[114] View Article

[115] Google Scholar

[ref40] 40. Knoll U, Glünder G, Kietzmann M (1999) Comparative study of the plasma pharmacokinetics and tissue concentrations of danofloxacin and enrofloxacin in broiler chickens. J Vet Pharmacol Ther 22: 239-246. doi:https://doi.org/10.1046/j.1365-2885.1999.00217.x. PubMed: 10499235.
View Article
Google Scholar

[117] View Article

[118] Google Scholar

[ref41] 41. Pozzin JF, Harron DWJ, Nation G, Tinson AH, Sheen R et al. (1997) Pharmacoknetics of enrofloxacin following intravenous/intramuscular/oral administration in Nedji sheep. J Vet Pharmacol Ther 20 (Suppl. 1): 60-61.
View Article
Google Scholar

[120] View Article

[121] Google Scholar

[ref42] 42. Gyrd-Hansen N, Nielsen P (1994) he influence of feed on the oral bioavailability of enrofloxacin, oxytetracycline, penicillin V and spiramycin in pigs [poster communications]. pp. 242-243.

[ref43] 43. Alvarez AI, Pérez M, Prieto JG, Molina AJ, Real R et al. (2008) Fluoroquinolone efflux mediated by ABC transporters. J Pharmacol Sci 97: 3483-3493. doi:https://doi.org/10.1002/jps.21233. PubMed: 18200507.
View Article
Google Scholar

[124] View Article

[125] Google Scholar

[ref44] 44. Conzelman GM, Babish JG, Davidson JN, McMillan RA, Copeland DD (1987) Pharmacokinetics of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethyl-1-piperazinyl)-3-q uinoline- carboxylic acid (BAY Vp 2674) in chickens. Proc West Pharmacol Soc 30: 393-395. PubMed: 3628311.
View Article
Google Scholar

[127] View Article

[128] Google Scholar

[ref45] 45. Anadón A, Martínez-Larrañaga MR, Díaz MJ, Bringas P, Martínez MA et al. (1995) Pharmacokinetics and residues of enrofloxacin in chickens. Am J Vet Res 56: 501-506. PubMed: 7785830.
View Article
Google Scholar

[130] View Article

[131] Google Scholar

[ref46] 46. Seguin MA, Papich MG, Sigle KJ, Gibson NM, Levy JK (2004) Pharmacokinetics of enrofloxacin in neonatal kittens. Am J Vet Res 65: 350-356. doi:https://doi.org/10.2460/ajvr.2004.65.350. PubMed: 15027685.
View Article
Google Scholar

[133] View Article

[134] Google Scholar

Figures

Abstract

Introduction

Materials and Methods

Reagents and drugs

Animals and sample collection

RNA isolation and mRNA quantification

Immunohistochemistry

Experiments with enrofloxacin in broilers

Assay for enrofloxacin in serum by HPLC

Pharmacokinetic analysis

Data analysis

Results

Age-dependent mRNA expression in liver and small intestines in broilers

The cellular localisation and quantification of P-gp in liver and small intestines of broilers

Pharmacokinetics of enrofloxacin with a single application in broilers at different ages

Effect of verapamil on pharmacokinetics of orally administrated enrofloxacin

Effect of verapamil on pharmacokinetics of i.v. administered enrofloxacin

Discussion

Acknowledgments

Author Contributions

References